Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
for Generalized Myasthenia Gravis
3 locations incl. Chicago
Sponsor: argenx
Sex: All·Age: 2 - 18
Code: NCT04833894·Phase 2, Phase 3·Recruiting